GDTC•globenewswire•
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
Summary
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company’s research programs, clinical progress, and operations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 28, 2026 by globenewswire